arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

VYNE Therapeutics Inc.

VYNE
$28.05 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
39 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
53
Health
Fair
Moderately Bearish
auto_awesome

Analytical Summary

VYNE Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $1.2B
Dividend Yield
Revenue Growth -57.4%
Op. Margin None
ROIC -15.5%
FCF / Share $-0.10
Trailing P/E
Price / Book 38.0x
FCF Yield
Debt / Equity 0.00
info Valuation on last close. End-of-day price, Jul 27, 2026.

39-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$86.00K
↓ -57.4%
Net Income Profit after all expenses
$-3.58M
↑ +58.4%
Operating Margin Operating profit as % of sales
-435.0%
↑ +1.4%
FCF / Share Free cash flow per share
$-0.10
↑ +64.5%
Long-Term Debt Long-term obligations
$0.00
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
9
Financial Health
97
Cash Quality
74

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 12 years · 39 quarters